2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIOGUANYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIOADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-CYTIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENEGUANOSINE – Applicazione in terapia e ricerche cliniche attuali

2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIOGUANYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIOADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-CYTIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENEGUANOSINE

FAQ

Sperimentazioni cliniche in corso su 2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIOGUANYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIOADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-CYTIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENEGUANOSINE

Studio sull’Efficacia e Sicurezza a Lungo Termine di GTX-102 nei Pazienti con Sindrome di Angelman

In arruolamento

3 1 1
Malattie in studio:
- Sindrome di Angelman
Farmaci in studio: